Spanish flag Español
Medicina Interna Basada en la Evidencia

Portal para médicos

Alteraciones de la hemostasia: avances de 2021/2022

12.12.2022
Título original: Zaburzenia hemostazy – postępy 2021/2022
Autor: Jerzy Windyga (MD, PhD)

Nota: la revisión de las publicaciones abarca el período comprendido entre el 06/08/2021 y el 06/05/2022.

Siglas y abreviaturas: aFL — anticuerpos antifosfolipídicos, ASH — American Society of Hematology, CCPa — concentrados de complejo protrombínico activado, COVID-19 — enfermedad por coronavirus de 2019, ECA — ensayo controlado aleatorizado, EP — embolismo pulmonar, ET — evento tromboembólico, ETV — enfermedad tromboembólica venosa, EVW — enfermedad de Von Willebrand, FVIII — factor de coagulación VIII, FVW — factor de Von Willebrand, Hb — hemoglobina, HPN — hemoglobinuria paroxística nocturna, IC — intervalo de confianza, ISTH — International Society on Thrombosis and Haemostasis, ITI — inducción de tolerancia inmunológica, LD-RIPA — agregación plaquetaria inducida por ristocetina a dosis bajas, MAT — microangiopatía trombótica, MHRA — Medicines and Healthcare products Regulatory Agency, NET — trampas extracelulares de los neutrófilos, NHF — National Hemophilia Foundation, PTI — púrpura trombocitopénica inmune, PTT — púrpura trombocitopénica trombótica, SAFc — síndrome antifosfolipídico catastrófico, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) — coronavirus 2 del síndrome respiratorio agudo grave, TAS — tasa anualizada de sangrado, TP — tiempo de protrombina, TTPa — tiempo de tromboplastina parcial activada, TVP — trombosis venosa profunda, UB — Unidad Bethesda, UKHCDO — United Kingdom Haemophilia Centre Doctors’ Organization, WFH — World Federation of Haemophilia, VITT (vaccine-induced thrombotic thrombocytopenia) — trombocitopenia inmune trombótica inducida por vacuna

Bibliografía:
  1. Greinacher A., Thiele T., Warkentin T.E. y cols., Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, N. Engl. J. Med., 2021; 384: 2092-2101
  2. Schultz N.H., Sorvoll I.H., Michelsen A.E. y cols., Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination, N. Engl. J. Med., 2021; 384: 2124-2130
  3. Scully M., Singh D., Lown R. y cols., Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination, N. Engl. J. Med., 2021; 384: 2202-2211
  4. Muir K.L., Kallam A., Koepsell S.A., Gundabolu K., Thrombotic thrombocytopenia after Ad26.COV2.S vaccination, N. Engl. J. Med., 2021; 384: 1964-1965
  5. Windyga J., Zaburzenia hemostazy – postępy 2020/2021, Med. Prakt., 2021; 9: 62-69
  6. Makris M., Pavord S., Lester W. y cols., Vaccine-induced immune thrombocytopenia and thrombosis (VITT), Res. Pract. Thromb. Haemost., 2021; 5: e12 529
  7. Pavord S., Scully M., Hunt B.J. y cols., Clinical features of vaccineinduced immune thrombocytopenia and thrombosis, N. Engl. J. Med., 2021; 385: 1680-1689
  8. Medicines and Healthcare products Regulations Agency: Coronavirus vaccine – summary of Yellow Card, https://tinyurl.com/uwx6jpjh (acceso 26.07.2021)
  9. Arepally G.M., Ortel T.L., Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know, Blood, 2021; 138: 293-298
  10. See I., Su J.R., Lale A. y cols., US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021, JAMA, 2021; 325: 2448-2456
  11. Klok F.A., Pai M., Huisman M.V., Makris M., Vaccine-induced immune thrombotic thrombocytopenia, Lancet Haematol., 2022; 9: e73-e80
  12. Pavord S., Hunt B.J., Horner D. y cols.; Guideline Committee: Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance, BMJ, 2021; doi: 10.1136/bmj.n2195
  13. Warkentin T.E., Greinacher A., Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia, Thromb. Res., 2021; 204: 40-51
  14. Rollin J., Pouplard C., Gruel Y., Risk factors for heparin-induced thrombocytopenia: focus on Fcγ receptors, Thromb. Haemost., 2016; 116: 799-805
  15. Perdomo J., Leung H.H.L., Ahmadi Z. y cols., Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia, Nat. Commun., 2019; 10: 1322
  16. Khandelwal S., Barnes A., Rauova L. y cols., Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes, Blood, 2021, 138: 2106-2116
  17. Schönborn L., Thiele T., Kaderali L. y cols., Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient, Blood, 2022, 139: 1903-1907
  18. Schönborn L., Thiele T., Kaderali L., Greinacher A., Decline in pathogenic antibodies over time in VITT, N. Engl. J. Med., 2021; 385: 1815-1816
  19. Lacy J., Pavord S., Brown K.E., VITT and second doses of Covid-19 vaccine, N. Engl. J. Med., 2022; doi: 10.1056/NEJMc2 118 507
  20. Lyman G.H., Carrier M., Ay C. y cols., American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer, Blood Adv., 2021; 5: 927-974
  21. Windyga J., Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej u chorych na nowotwór złośliwy. Omówienie wytycznych American Society of Hematology 2021, Med. Prakt., 2021; 7-8: 8-15
  22. Zheng X.L., Vesely S.K., Cataland S.R. y cols., ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura, J. Thromb. Haemost., 2020; 18: 2486-2495
  23. Zheng X.L., Vesely S.K. Cataland S.R. y cols., ISTH guidelines for treatment of thrombotic thrombocytopenic purpura, J. Thromb. Haemost., 2020; 18: 2496-2502
  24. Windyga J., Rozpoznanie i leczenie zakrzepowej plamicy małopłytkowej. Omówienie wytycznych International Society on Thrombosis and Haemostasis, Med. Prakt., 2021; 12: 60-68
  25. James P.D., Connell N.T., Ameer B. y cols., ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease, Blood Adv., 2021; 5: 280-300
  26. Connell N.T., Flood V.H., Brignardello-Petersen R. y cols., ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease, Blood Adv., 2021; 5: 301-325
  27. Shui M., D’Angelo L., Croteau S.E., Diagnostic and therapeutic decision making in pediatric patients with low von Willebrand factor, Blood, 2019; doi: 10.1182/blood-2019-123 734
  28. Bowman M.L., James P.D., Controversies in the diagnosis of type 1 von Willebrand disease, Int. Jnl. Lab. Hem., 2017; 39 (supl. 1): 61-68
  29. Flood V.H., Gill J.C., Friedman K.D. y cols., Collagen binding provides a sensitive screen for variant von Willebrand disease, Clin. Chem., 2013, 59: 684-691
  30. Windyga J., Emicizumab in severe hemophilia A, Acta Haematol. Pol., 2021; 52: 422-428
  31. Callaghan M.U., Negrier C., Paz-Priel I. y cols., Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies, Blood, 2021, 137: 2231-2242
  32. Oldenburg J., Mahlangu J.N., Kim B. y cols., Emicizumab prophylaxis in hemophilia A with inhibitors, N. Engl. J. Med., 2017; 377: 809-818
  33. Hart D.P., Alamelu J., Bhatnagar N. y cols., Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update, Haemophilia, 2021; 27: 932-937
  34. Klamroth R., Windyga J., Radulescu V. y cols., Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study, Blood, 2021, 137: 1818-1827
  35. Windyga J., Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej u chorych na nowotwór złośliwy. Omówienie wytycznych American Society of Hematology 2021, Med. Prakt., 2021; 7-8: 8-15
  36. Lee J.W., Sicre de Fontbrune F., Wong Lee L. y cols., Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study, Blood, 2019, 133: 530-539
  37. Kulasekararaj A.G., Hill A., Rottinghaus S.T. y cols., Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study, Blood, 2019, 133: 540-549
  38. Hillmen P., Szer J., Weitz I. y cols., Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria, N. Engl. J. Med., 2021; 384: 1028-1037
  39. Kulasekararaj A.G., Risitano A.M., Maciejewski J.P. y cols., Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab, Blood, 2021, 138: 1928-1938